Xoma Royalty Revenue Growth Rates (XOMA), Current and Historic Growth - CSIMarket
CSIMarket Company Name, Ticker, Suppliers, else..
 


• Revenue Y/Y
• Op. Income Y/Y
• Cop. Income Y/Y
• Net Income Y/Y
• Eps Cop. Y/Y
• Eps Net Y/Y
• Free Cash Flow Y/Y
• Cash Flow Y/Y
• Capex Y/Y
• Sales Y/Y Annual
Xoma Royalty Corporation  (NASDAQ: XOMA)
 

XOMA's Revenue Growth by Quarter and Year

Xoma Royalty's Revenue results by quarter and year



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

XOMA Revenue (in millions $) FY 2026 FY 2025 FY 2024 FY 2023
4th Quarter December -
3rd Quarter September -
2nd Quarter June -
1st Quarter March 12.32
FY 12.32

XOMAs Annual Revenue
Xoma Royalty's Revenue in the fiscal year 2025 $ 52.15 millions
Xoma Royalty's Revenue in the fiscal year 2024 $ 28.49 millions
Xoma Royalty's Revenue in the fiscal year 2023 $ 4.76 millions
Xoma Royalty's Revenue in the fiscal year 2022 $ 6.03 millions
Xoma Royalty's Revenue in the fiscal year 2021 $ 38.16 millions




XOMA Revenue first quarter 2026 Y/Y Growth Comment
Xoma Royalty Corporation reported decline in Revenue in the first quarter 2026 by -22.58% to $ 12.32 millions, from the same quarter in 2025.
The contraction in the first quarter 2026 Xoma Royalty Corporation's Revenue compares unfavorably to the Company's average Revenue doubling of 178.63%.

Looking into first quarter 2026 results within Major Pharmaceutical Preparations industry 41 other companies have achieved higher Revenue growth. While Xoma Royalty Corporation' s Revenue fall of -22.58% ranks overall at the positon no. 255 in the first quarter 2026.


XOMA Revenue ( Y/Y Growth %) 2026
 2025 2024 2023
4th Quarter December - 57.98 % 375.96 % 22.82 %
3rd Quarter September - 29.86 % 767.47 % 84.44 %
2nd Quarter June - 18.39 % 568.07 % 69.39 %
1st Quarter March -22.58 % 967.79 % 238.64 % -85.85 %
FY   - 83.05 % 498.53 % -

Financial Statements
Xoma Royalty's first quarter 2026 Revenue $ 12.32 millions XOMA's Income Statement
Xoma Royalty's first quarter 2025 Revenue $ 15.91 millions Quarterly XOMA's Income Statement


XOMA Revenue (Quarter on Quarter Growth %)

 2026
 2025 2024 2023
4th Quarter December - 47.17 % 20.97 % 120.48 %
3rd Quarter September - -28.79 % -35.08 % -50 %
2nd Quarter June - -17.47 % 644.3 % 277.27 %
1st Quarter March -10.48 % 82.66 % -18.58 % -70.47 %
FY (Year on Year)   - 83.05 % 498.53 % -


Back to XOMA Growth rate Comparisons >> Back to XOMA Growth rate Comparisons >>


Revenue first quarter 2026 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #42
Healthcare Sector #78
Overall #255

Revenue Y/Y Growth Statistics
High Average Low
2740.66 % 178.63 % -95.12 %
(Mar 31 2018)   (Mar 31 2023)
Revenue first quarter 2026 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #42
Healthcare Sector #78
Overall #255
Revenue Y/Y Growth Statistics
High Average Low
2740.66 % 178.63 % -95.12 %
(Mar 31 2018)   (Mar 31 2023)

Revenue by Quarter for the Fiscal Years 2023, 2024, 2025, 2026

Xoma Royalty's Q/Q Revenue Growth


Revenue Q/Q Growth Statistics
High Average Low
4931.24 % 224.85 % -100 %
(Dec 31 2020)  


XOMA's I. Quarter Q/Q Revenue Comment
In the I. Quarter 2026 Xoma Royalty Corporation disclosed drop in Revenue from the fourth quarter by -10.48% to $ 12.32 millions, from $ 13.76 millions achived in the previous reporting period.

Although periodic circumstance commonly energize I. Quarter 2026 Revenue, this plainly could not be substantial to rescue Major Pharmaceutical Preparations's company achievement, Most analysts pointed out.

Within Major Pharmaceutical Preparations industry 110 other companies have achieved higher Revenue quarter on quarter growth. While Xoma Royalty's Revenue growth quarter on quarter, overall rank is 2490.


Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #111
Healthcare Sector #317
Overall #2490
Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #111
Healthcare Sector #317
Overall #2490
Revenue Q/Q Growth Statistics
High Average Low
4931.24 % 224.85 % -100 %
(Dec 31 2020)  


XOMA's I. Quarter Q/Q Revenue Comment
In the I. Quarter 2026 Xoma Royalty Corporation disclosed drop in Revenue from the fourth quarter by -10.48% to $ 12.32 millions, from $ 13.76 millions achived in the previous reporting period.

Although periodic circumstance commonly energize I. Quarter 2026 Revenue, this plainly could not be substantial to rescue Major Pharmaceutical Preparations's company achievement, Most analysts pointed out.

Within Major Pharmaceutical Preparations industry 110 other companies have achieved higher Revenue quarter on quarter growth. While Xoma Royalty's Revenue growth quarter on quarter, overall rank is 2490.


Xoma Royalty's 12 Months Revenue Growth Year on Year


Revenue TTM Growth

12 Months Ending
(Mar 31 2026)		 12 Months Ending
(Dec 31 2025)		 12 Months Ending
(Sep 30 2025)		 12 Months Ending
(Jun 30 2025)		 12 Months Ending
(Mar 31 2025)
Cumulative Revenue 12 Months Ending $ 48.56 $ 52.15 $ 47.11 $ 44.95 $ 42.91
Y / Y Revenue Growth (TTM) 13.16 % 83.06 % 118.02 % 194.98 % 638.41 %
Year on Year Revenue Growth Overall Ranking # 26 # 22 # 17 # 43 # 104
Seqeuential Revenue Change (TTM) -6.89 % 10.71 % 4.79 % 4.76 % 50.63 %
Seq. Revenue Growth (TTM) Overall Ranking # 287 # 344 # 160 # 69 # 423


Cumulative Revenue growth Comment
With the quarterly Revenue reported in the Mar 31 2026 period, Xoma Royalty's cumulative twelve months Revenue were $ 49 millions, company would post below average annual Revenue growth of 50.63% year on year, if the fiscal year would end at Mar 31 2026.
A slow-down in the Xoma Royalty's Revenue growth from the 13.76% growth in Dec 31 2025.

Among companies within the Healthcare sector 9 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 22 to 26.

Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 45
Healthcare Sector # 10
Overall # 26

Revenue TTM Y/Y Growth Statistics
High Average Low
2740.66 %
 178.63 %
-95.12 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 45
Sector # 84
S&P 500 # 287
Cumulative Revenue growth Comment
With the quarterly Revenue reported in the Mar 31 2026 period, Xoma Royalty's cumulative twelve months Revenue were $ 49 millions, company would post below average annual Revenue growth of -95.12% year on year, if the fiscal year would end at Mar 31 2026.
A slow-down in the Xoma Royalty's Revenue growth from the 13.76% growth in Dec 31 2025.

Among companies within the Healthcare sector 9 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 22 to 26.


Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 45
Healthcare Sector # 10
Overall # 26

Revenue TTM Y/Y Growth Statistics
High Average Low
2740.66 %
178.63 %
-95.12 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 45
Sector # 84
S&P 500 # 287




Other Revenue Growth
Major Pharmaceutical Preparations Industry Revenue Growth Trends and Statistics
Healthcare Sector Revenue Growth Statistics
Revenue Growth Trends for overall market
XOMA's Revenue Growth Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Revenue Growth
Lowest Ranking Revenue Growth




Companies with similar Revenue drop for the quarter ending Mar 31 2026 within Healthcare SectorY/Y Change %Revenue for the quarter ending Mar 31 2026
Trisalus Life Sciences Inc -0.03%$ -0.035 millions
Adma Biologics Inc -0.30%$ -0.304 millions
Vaso Corporation-0.54%$ -0.545 millions
60 Degrees Pharmaceuticals Inc -0.92%$ -0.922 millions
Cytosorbents Corporation-0.95%$ -0.945 millions
Conmed Corporation-1.31%$ -1.310 millions
Neuropace Inc -1.32%$ -1.316 millions
Bio techne Corp-1.35%$ -1.353 millions
Schrodinger Inc -1.62%$ -1.619 millions
United Therapeutics Corporation-1.62%$ -1.624 millions
Prokidney Corp -1.74%$ -1.739 millions
Sarepta Therapeutics Inc -1.89%$ -1.887 millions
Fortrea Holdings Inc -2.27%$ -2.272 millions
Ultragenyx Pharmaceutical Inc -2.36%$ -2.363 millions
Teladoc Health Inc -2.47%$ -2.467 millions
Fonar Corporation-2.55%$ -2.551 millions
Puma Biotechnology Inc -2.59%$ -2.593 millions
Coya Therapeutics Inc -2.61%$ -2.612 millions
10x Genomics Inc -2.76%$ -2.763 millions
Plus Therapeutics Inc -2.93%$ -2.927 millions
Infusystem Holdings Inc-2.97%$ -2.973 millions
Solventum Corporation-3.04%$ -3.043 millions
Milestone Scientific Inc -3.15%$ -3.153 millions
Organon and Co -3.50%$ -3.503 millions
Fulgent Genetics Inc -3.89%$ -3.894 millions
Igc Pharma Inc -3.94%$ -3.939 millions
Carlisle Companies Incorporated-3.99%$ -3.988 millions
Harvard Bioscience Inc -4.44%$ -4.437 millions
Castle Biosciences Inc -4.90%$ -4.897 millions
Prestige Consumer Healthcare Inc -4.95%$ -4.953 millions


About Xoma Royalty Revenue Growth Rates (XOMA), Current and Historic Growth - CSIMarket Analysis

How we calculate this

This page is based on issuer-reported fundamentals and CSIMarket’s U.S. equities database (20+ years). Growth is computed using year-over-year (Y/Y), sequential, and trailing-twelve-month (TTM) methods.

What’s included here

Company: Xoma Royalty Corp (CIK 791908).

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings → XBRL parse → normalization CSIMarket.com Database → growth calculations.
  • Accession: 0001104659-26-059369
  • Figures are derived from filed reports and may be restated; numbers are subject to revision.

Sources: Xoma Royalty Corp’s SEC filings (XBRL/Inline XBRL) and CSIMarket.com’s normalization & QA processes.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.